Wide Ranks

BIVI

BioVie Inc.

2.71

Top Statistics
Market Cap 48 M Forward PE -0.6145 Revenue Growth 0.00 %
Current Ratio 2.57 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.2340 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 23 M Total Cash Per Share 3.01 Total Debt 6 M
Total Debt To Equity 39.41 Current Ratio 2.57 Book Value Per Share 2.50
All Measures
Short Ratio 15.00 % Message Board Id finmb_242387715 Shares Short Prior Month 383126
Return On Equity -2.08 City Carson City Uuid eb7eacbe-6abc-3b57-b586-2bc16fc1c3b3
Previous Close 2.82 First Trade Date Epoch Utc 1 B Book Value 2.50
Beta 0.9020 Total Debt 6 M Volume 1 M
Price To Book 1.08 Last Split Date 1 B Fifty Two Week Low 1.04
Total Cash Per Share 3.01 Shares Short Previous Month Date 1 B Target Median Price 5.00
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 5.00
Net Income To Common -33006956 Short Percent Of Float 0.1252 Implied Shares Outstanding 17 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M
Average Volume10days 2 M Total Cash 23 M Next Fiscal Year End 1 B
Held Percent Insiders 0.1369 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.82 Target Low Price 5.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.27 Open 2.86
Free Cashflow -18778568 State NV Dividend Yield 0.00 %
Return On Assets -0.6669 Time Zone Short Name EST Trailing Eps -5.08
Day Low 2.67 Address1 680 West Nye Lane Shares Outstanding 17 M
Price Hint 4 Target High Price 5.00 Website https://bioviepharma.com
52 Week Change -0.8494 Average Volume 5 M Forward Eps -4.41
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 255.00 %
Last Split Factor 1:10 Regular Market Day High 2.88 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 39.41 Fifty Two Week High 33.10
Day High 2.88 Shares Short 1 M Regular Market Open 2.86
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.1082 Operating Cashflow -27945024 Currency USD
Time Zone Full Name America/New_York Market Cap 48 M Is_nasdaq_100 False
Zip 89703 Quote Type EQUITY Industry Biotechnology
Long Name BioVie Inc. Regular Market Day Low 2.67 Held Percent Institutions 0.0999
Current Price 2.71 Address2 Suite 204 Enterprise To Ebitda -0.2340
Financial Currency USD Current Ratio 2.57 Industry Disp Biotechnology
Number Of Analyst Opinions 1 Country United States Float Shares 4 M
Two Hundred Day Average 4.43 Enterprise Value 7 M Forward PE -0.6145
Regular Market Volume 1 M Ebitda -31950208 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease.

The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis.

It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program.

The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.

BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.